Tazbentetol - Spinogenix
Alternative Names: SPG-302; Tazbentetol-SpinogenixLatest Information Update: 12 May 2026
At a glance
- Originator Spinogenix
- Class Antidementias; Antiglaucomas; Antineoplastics; Antipsychotics; Benzene derivatives; Benzothiazoles; Ethylene glycols; Eye disorder therapies; Neuroprotectants; Small molecules
- Mechanism of Action Synaptic transmission modulators
-
Orphan Drug Status
Yes - Amyotrophic lateral sclerosis
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease; Amyotrophic lateral sclerosis; Schizophrenia
- Preclinical Diabetic retinopathy; Glaucoma
Most Recent Events
- 05 May 2026 Tazbentetol - Spinogenix receives Fast Track designation for Amyotrophic lateral sclerosis [PO] in USA
- 03 May 2026 Preclinical trials in Diabetic retinopathy in USA (PO) prior to May 2026
- 03 May 2026 Pharmacodynamics data from the preclinical studies in Glaucoma and Diabetic retinopathy released by Spinogenix